486 Liquid biopsy-based analysis using cell-free DNA from melanoma patients

Since the demonstrated clinical success of BRAF/MEK inhibitors in patients with metastatic melanoma harboring BRAF mutations, attention has been focused on liquid biopsy to detect mutations cell-free DNA (cfDNA) using droplet digital PCR (ddPCR) or next-generation sequencing methods. In this study, we investigated gene tumor and cfDNA collected from 43 evaluate their potential as biomarkers. ddPCR CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) techniques were performed plasma obtained melanoma. The sensitivity specificity for mutation detection 54.5 % 100 %, respectively. Additionally, variants, including NRAS, TP53, GNAS, MET, detectable cfDNA, results partially consistent those identified tissues. Among variants examined, copy numbers MET disease status two treated a inhibitor. conclusion, CAPP-Seq presence especially when tissue biopsies are unavailable. may be biomarker